QIAGEN Accepts €46.50 Takeover; Law Firm Questions Price
QIAGEN's board unanimously approved EQT's €46.50 takeover bid, but shareholder law firm Halper Sadeh LLC promptly questioned whether the price is adequate. With institutions holding 79.5% of shares, t
QIAGEN Accepts €9.6B EQT Buyout; Law Firm Investigates
NEW YORK, October 26 —
QIAGEN N.V. (QGEN) accepted EQT AB's €9.6 billion takeover offer at €46.50 per share, with the board unanimous; shareholder law firm Halper Sadeh LLC promptly questioned whether that consideration is adequate. Bank of America, having assembled a 5.73% stake via shares and derivatives, holds a position that matters in a register that is 79.5% institutionally owned.
- Crown NL Bidco, backed by EQT AB, agreed to acquire QIAGEN at €46.50 per share in a €9.6 billion deal.
- Bank of America built a 5.73% stake in QIAGEN through shares and derivatives, per filings.
- QIAGEN generated $373 million in free cash flow on $2.10 billion in trailing revenue at a 66.4% gross margin.
A Profitable Franchise, Not a Growth Story
QIAGEN N.V. builds molecular diagnostics tools spanning nucleic acid purification kits, PCR instruments, and clinical assays: its QuantiFERON-TB product is a flagship for tuberculosis testing, while the broader portfolio covers HPV screening, post-transplant monitoring, and next-generation sequencing. That mix generated $2.10 billion in trailing revenue at a 66.4% gross margin, a high-consumables profile that translated to $654 million in operating cash flow and $373 million in free cash flow. Growth was 0.3% trailing, flat entering the deal, yet QIAGEN beat consensus EPS estimates in each of its last four quarters, most recently $0.62 against a estimate. EQT is acquiring durability, not acceleration.
The Institutional Vote Will Decide This
With insiders holding only 0.5% of QIAGEN shares, the shareholder vote falls almost entirely to the 79.5% institutional cohort, a structure that makes Bank of America's assembled stake consequential regardless of that firm's stated posture. Halper Sadeh LLC's investigation into whether shareholders are receiving adequate consideration creates a formal mechanism for large holders to contest the terms, separate from any portfolio-level decision. QIAGEN shares rose 5.0% as the EQT deal came into focus; the consensus analyst price target at $49.20 gives institutions an external benchmark as they evaluate the announced consideration.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| QGEN | $10.4B | 19.3x | +4.1% |
| TECH | $11.4B | 31.4x | +12.9% |
| BIO | $10.0B | 38.2x | +10.1% |
| CRL | $17.1B | 28.0x | +76.9% |
| MYGN | $576M | n/a | -28.1% |
| QDEL | $944M | 9.6x | -53.4% |
What Institutions Will Weigh Before the Vote
The shareholder vote arrives against a balance sheet of $790 million in cash and $1.65 billion in debt. QIAGEN trades at a 19.3x forward P/E; how that valuation sits against €46.50 will anchor the adequacy argument, alongside a DCF model of the franchise's cash generation. A rating downgrade reported alongside news of the deal nearing close signals a change in analytical focus from underlying fundamentals to deal outcome. Run the free Qiagen N.V. deep-dive → for live numbers entering any vote.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What is the QIAGEN EQT deal price?
EQT has agreed to acquire QIAGEN at €46.50 per share in a €9.6 billion transaction. The deal was unanimously approved by QIAGEN's board of directors.
Why did Halper Sadeh question the deal?
Shareholder law firm Halper Sadeh LLC launched an investigation into whether the €46.50 consideration is adequate for QIAGEN shareholders. The investigation creates a formal mechanism for large holders to contest the terms separate from any portfolio-level decision.
How much institutional ownership does QIAGEN have?
Institutional investors hold 79.5% of QIAGEN shares, with insiders holding only 0.5%. This concentration means the shareholder vote will be decided almost entirely by large institutional holders.
What is QIAGEN's current financial performance?
QIAGEN generated $2.10 billion in trailing revenue at a 66.4% gross margin, with $373 million in free cash flow. The company beat consensus EPS estimates in each of its last four quarters, most recently $0.62 against a $0.599 estimate.
What metrics will institutions weigh to evaluate the deal?
Institutions will assess whether the 19.3x forward P/E valuation sits fairly against €46.50, alongside a DCF model of the franchise's cash generation. The analyst consensus price target of $49.20 provides an external benchmark for their evaluation.
Crown NL Bidco, backed by Swedish private equity firm EQT AB, agreed to acquire QIAGEN N.V. at €46.50 per share in a deal valued at approximately €9.6 billion, and the board issued unanimous acceptance. But shareholder law firm Halper Sadeh LLC promptly launched an investigation into whether the terms adequately compensate shareholders, and Bank of America separately assembled a 5.73% stake via shares and derivatives.